Description

Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA)[1].–20°C, 3 years (Powder)-Applications-Cancer-programmed cell death-Formula-C33H45N5O9-Citation–References-[1]Benešová M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15(3):934-946.-CASNumber-1703768-74-4-MolecularWeight-655.74-Compound Purity-99.95-SMILES-O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CN)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O-Research_Area-Cancer-Solubility-DMSO : 125 mg/mL (ultrasonic)-Target-ADC Linker-Isoform-Non-cleavable Linker-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related